Royce & Associates’s NuVasive, Inc. NUVA Stock Holding History

Royce & Associates’s Portfolio NUVA Stock Details NUVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-823	Closed	-$42K	–	1238
2020 Q1	$42K	Buy	+823	New	+$55.2K	﹤0.01%	1030
2019 Q3	–	Sell	-572	Closed	-$33K	–	1193
2019 Q2	$33K	Sell	572 -106	-16%	-$6.26K	﹤0.01%	1072
2019 Q1	$39K	Buy	678 +176	+35%	+$9.36K	﹤0.01%	1062
2018 Q4	$25K	Buy	+502	New	+$30.2K	﹤0.01%	1073
2018 Q3	–	Sell	-365	Closed	-$19K	–	1233
2018 Q2	$19K	Buy	+365	New	+$19.1K	﹤0.01%	1135

Other funds holding NUVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACA

Anchor Capital Advisors Boston, Massachusetts $3.56B AUM 21.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Royce & Associates's NUVA Position: Q2 2020 in Review

Royce & Associates sold out of NuVasive, Inc. (NUVA) in Q2 2020, closing a stake of 823 shares — an estimated $42K sold.

Royce & Associates first reported a position in NUVA in Q2 2018 and held it in 5 quarters. The position peaked at $42K in Q1 2020. 290 funds tracked by Wall St. Rank hold NUVA as of Q2 2020.

Royce & Associates reported no remaining NuVasive, Inc. position as of Q2 2020 after selling out during the quarter.
Royce & Associates sold 823 NuVasive, Inc. shares in Q2 2020, an estimated $42K.
Royce & Associates first reported a position in NuVasive, Inc. in Q2 2018 and held it in 5 quarters.
Royce & Associates's NuVasive, Inc. position peaked at $42K in Q1 2020.
290 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q2 2020.

Based on Royce & Associates's 13F filing for Q2 2020, filed 7 Aug 2020.